MARKET

OMER

OMER

Omeros
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.10
+0.27
+2.75%
Opening 15:32 09/25 EDT
OPEN
9.89
PREV CLOSE
9.83
HIGH
10.25
LOW
9.87
VOLUME
902.59K
TURNOVER
--
52 WEEK HIGH
25.46
52 WEEK LOW
8.50
MARKET CAP
620.30M
P/E (TTM)
-4.9122
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Key Things To Understand About Omeros' (NASDAQ:OMER) CEO Pay Cheque
This article will reflect on the compensation paid to Greg Demopulos who has served as CEO of Omeros Corporation...
Simply Wall St. · 09/14 19:10
Omeros to Present at the Cantor Virtual Global Healthcare Conference
Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week. The presentation is scheduled for Tuesday, September 15, 2020 at 11:20 a.m. EDT.
Business Wire · 09/11 12:00
Omeros (OMER) Catches Eye: Stock Jumps 6%
Zacks · 09/09 13:45
Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients
Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. The panel session, entitled Lessons from Bergamo: Discoveries in Treating Critically-ill COVID-19 Patients, was held on September
Business Wire · 09/03 14:38
Omeros Shares Quiet; Omeros Highlights Co's Investigational Agent Narsoplimab Discussed At Demy-Colton Virtual Salon Series As 'Potentially Highly Effective Therapy' In Critically Ill COVID-19 Patients
Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients - Omeros' investigational agent narsoplimab discussed as a potentially highly effective
Benzinga · 09/03 13:43
How Does Omeros's Debt Look?
Over the past three months, shares of Omeros Inc. (NASDAQ: OMER) moved lower by 13.52%. Before having a look at the importance of debt, let's look at how much debt Omeros has.Omeros's Debt Based on Omeros's balance sheet as of August 10, 2020, long-term debt is at $164.46 million and current
Benzinga · 08/31 13:18
Omeros' COVID-19 Opportunity And Challenges
Omeros' old story, with its heavy reliance on OMIDRIA revenues, is drifting away.Omeros' initial success in treating COVID-19 presents intriguing possibilities.Narsoplimab in the treatment of an orphan application, such as stem cell TMA, pairs uncomfortably with the treatment of COVID-19.
Seekingalpha · 08/17 18:53
Omeros stock price target cut to $20 from $25 at Maxim Group
OMER | Complete Omeros Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 08/14 11:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OMER. Analyze the recent business situations of Omeros through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OMER stock price target is 34.60 with a high estimate of 75.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 171
Institutional Holdings: 33.75M
% Owned: 54.95%
Shares Outstanding: 61.42M
TypeInstitutionsShares
Increased
48
1.58M
New
41
-306.39K
Decreased
32
775.31K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.31%
Pharmaceuticals & Medical Research
+1.42%
Key Executives
Chairman/President/Chief Executive Officer/Director
Gregory Demopulos
Chief Accounting Officer/Vice President - Finance/Treasurer
Michael Jacobsen
Chief Scientific Officer/Vice President
George Gaitanaris
Vice President/General Counsel/Secretary
Peter Cancelmo
Vice President
Christopher Bral
Vice President
Daniel Kirby
Vice President
Alexander Gragerov
Vice President
Bruce Meiklejohn
Vice President
Catherine Melfi
Vice President
Tina Quinton
Vice President
J. Steven Whitaker
Vice President - Business Development
Timothy Duffy
Lead Director/Independent Director
Thomas Cable
Director
Peter Demopulos
Independent Director
Ray Aspiri
Independent Director
Thomas Bumol
Independent Director
Arnold Hanish
Independent Director
Leroy Hood
Independent Director
Rajiv Shah
Independent Director
Kurt Zumwalt
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OMER
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Omeros Corporation stock information, including NASDAQ:OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.